Kornimate/medical-research-clean huggingface dataset:
chlorhexidine bathing to prevent hospital-acquired infections: the cleans study

Conditions: Chlorhexidine; Hospital-Acquired Infection; Surgery; Intensive Care Unit

Summary: hospital-acquired infections (hai) have been shown to increase length of hospital stay and mortality. infections acquired during a hospital stay have been shown to be preventable. the skin of patients is considered a major reservoir for pathogens associated with hospital-acquired infections, and has been suggested as a potential target for interventions to reduce bacterial burden and subsequent risk of infection. the use of daily chlorhexidine (chg) bathing in intensive care patients has been advocated to reduce many of the infections in critically ill patients. however, the effectiveness of chg bathing to reduce icu infections has varied considerably among published trials, making the effectiveness of chg bathing in icu patients uncertain.


Eligibility criteria:
inclusion criteria: * adults (≥ 18-years old) * anticipated sicu stay for 48 hours or more * apache ii \>15 exclusion criteria: * braden scale for predicting pressure sore risk score more than 9 (highest risk) * pregnancy * skin irritation * chlorhexidine allergy * sicu stay of more than 48 hours prior to screening
a study to understand the patients confirmed to have advanced or metastatic breast cancer and receiving palbociclib treatment using a real-world database

Conditions: Advanced or Metastatic Breast Cancer

Summary: the purpose of this real-world study is to look at breast cancer patients receiving palbociclib using a large real-world database collected under real-world practice. this study also looks at the safety of ibrance, including any side effects. side effects are undesired effects of a medicine or other type of treatment. this study will include the data of the following participants: * adult women (more than18 years of age) with at least one visit with a breast cancer * patients with locally advanced breast cancer or metastatic breast cancer with a staging classification of stage iii, stage iv. advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. metastatic cancer is the cancer which is spread from the place where it started to other places in the body. * patients with a laboratory test positive for hormone receptor and negative for her2 before or up to 60 days after advanced/metastatic breast cancer diagnosis date. * patients who received at least one initial prescription of ibrance following a diagnosis of advanced/metastatic breast cancer. this study will look at the safety of palbociclib treatment by looking at the number and severity of the side effects.


Eligibility criteria:
inclusion criteria patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: * adult women (≥ 18 years of age) with at least one visit with a breast cancer icd10 diagnosis code (c50.x) * patients with locally advanced breast cancer or metastatic breast cancer with a staging classification of stage iii, stage iv (distant metastases). * patients with a laboratory test positive for hormone receptor (hr) and negative for human epithelial growth factor receptor 2 (her2) before or up to 60 days after advanced/metastatic breast cancer diagnosis date. 1. hr-positive is defined as any positive test for estrogen receptor or progesterone receptor. 2. her2-negative is defined as any her2-negative test and the absence of a positive test (immunohistochemistry positive (3+), fluorescence in situ hybridization positive/amplified). * patients who received at least one initial prescription of ibrance following a diagnosis of advanced/metastatic breast cancer exclusion criteria patients meeting any of the following criteria will not be included in the study: * breast cancer with hr-negative and her2-positive on laboratory testing. * more than a 90-day gap between breast cancer diagnosis date and next visit. * patients who treated as off-label

Keywords: breast cancer palbociclib
yoga vs stretching in veterans with chronic lower back pain: does mindfulness matter?

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to demonstrate the feasibility of recruiting, enrolling and collecting outcome data on clbp patients within the veterans affairs community based rochester outpatient center who undergo an 8 week active exercise class with mindfulness (yoga) and without mindfulness (stretching class)

the study will approach all new or existing patients within the chiropractic clinic between the ages of 18 and 89 who have low back pain greater than 12 weeks and pain greater than or equal to 3, who have no contraindications to active exercise. patients will be queried as to interest and those interested will be consented. the investigators will recruit a total of 20 patients. patients will then be randomized to receive either an 8 week active exercise class with mindfulness (yoga) or an 8 week active exercise class without mindfulness (stretching class). both groups will have home exercise requirements and will be held accountable through the use of a home practice log. outcomes will include: pain (peg), quality of life (promis global health survey ghs), self efficacy (2 question), fear avoidance belief, castrophizing and social engagement. outcomes will be collected at baseline, and again at the end of the 8 week intervention. clinician open ended questionnaire will be given to both study clinicians at the end of the trial.

Eligibility criteria:
inclusion criteria: * adult veterans between the ages of 18-89 * lower back pain \> 12 weeks * have the ability to exercise independently. exclusion criteria: * subjects will be excluded if * they are currently enrolled in or maintain a home meditation practice * if they are currently involved in a mindfulness or cognitive behavioral therapy group. * if they have participated in a structured group yoga class in the last three months. * if they have an open workers compensation or no-fault case or have undergone spinal surgery in the past 6 months.
post-marketing surveillance of safety and effectiveness of mucosta®sr tab.

Conditions: Acute Gastritis; Chronic Gastritis

Summary: this pms is a non-interventional, prospective, single-arm, multi-center surveillance in accordance with korean regulation, 'standard for re-examination of new drugs'. this pms is to assess the safety and effectiveness after administrating mucosta®sr tab. each subject would be observed for 2 weeks from baseline, if possible. as this pms is an observational study in practical medical environment, the subject's follow-up is recommended but not obligatory and must be left up to the judgment of the investigator.

according to the "standards for re-examination of new drugs, etc." of south korea, this pms is conducted in order to collect safety and efficacy information for patients prescribed with mucosta®sr tab. under actual conditions of treatment during the re-examination period of mucosta®sr tab. 150mg (rebamipide)

Eligibility criteria:
inclusion criteria: 1. adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) in acute gastritis or acute exacerbation of chronic gastritis. 2. patients prescribed with mucosta®sr tab. according to the medical considerations of the investigator. 3. patients who have given a written informed consent to participation of this pms and use of personal information after execution of the contract with the surveillance study site. exclusion criteria: 1. patients with prior history of prescription with mucosta®sr tab. 2. patients with hypersensitivity to rebamipide or its component ingredients. 3. patients deemed not suitable for surveillance enrollment according to investigator's medical judgment
lifestyle hub pilot study

Conditions: Psychological Distress

Summary: this study will examine the effects of a smartphone-based lifestyle medicine (lm) for improving psychological well-being in chinese population. since a range of lifestyle factors are involved in the pathogenesis and progression of common mental disorders (e.g., depression and anxiety), modifying different lifestyle factors simultaneously may be effective to improve our psychological well-being. chinese dietary recommendations will be integrated into the app to increase the acceptability towards mental health intervention. through this study, we aim to promote evidence-based patient care and to improve help-seeking and access to evidence-based interventions for improving psychological well-being.

this study will be a randomized controlled trial on the effects of a culturally adapted self-help smartphone-based lifestyle medicine for improving psychological well-being in chinese population. prior to all study procedures, eligible participants will be required to complete an online informed consent (with telephone support). around 30 eligible participants will be randomly assigned to either smartphone-based lifestyle medicine (lm group) or the waitlist control group (wl group) in a ratio of 1:1.

Eligibility criteria:
inclusion criteria: * hong kong residents * aged ≥ 18 years * able to read chinese and type in chinese or english * have an internet-enabled mobile device (ios or android operating system) * are willing to provide informed consent and comply with the trial protocol exclusion criteria: * have a patient health questionnaire (phq-9) score ≥ 10 * have a generalized anxiety disorder 7-item scale (gad-7) ≥ 8 * current involvement in psychotherapy or unstable medication for depression and/or anxiety * beck depression inventory (bdi-ii) item 9 score of at least 2 indicating a current moderate suicidal risk that requires active crisis management (referral information to professional services will be provided to those with serious suicidal risk) * are having unsafe conditions and are not recommended for physical activity or a change in diet by physicians * having major psychiatric, medical or neurocognitive disorders that make participation infeasible or interfere with the adherence to the lifestyle modification

Keywords: psychological well-being lifestyle medicine self-help depression anxiety
retrospective evaluation of combination treatment with the ulthera system

Conditions: Skin Laxity

Summary: a retrospective study to evaluate the ulthera® system for its potential interaction with toxins and fillers. up to 500 subjects will be enrolled.

this is a retrospective, multi-site study involving chart reviews of subjects who have received an ultherapy treatment along with radiesse®, xeomin®, and/or belotero® balance within six months apart in the face and/or neck areas. enrolled subjects will have received an ultherapy treatment along with botulinum toxin a and/or filler treatment(s) within the last two years and with filler and toxin treatment occurring within 6 months before or after ultherapy.

Eligibility criteria:
inclusion criteria: * male or female, age 25 to 70 years. * subject in good health * subject must have had an ultherapy treatment and merz branded neurotoxin/filler treatments within 6 months of one or more ultherapy treatments. * subject must have had both ultherapy and neurotoxin/filler within the last 2 years (since april 2013) and with toxin/filler treatment within 6 months proximity to the ultherapy treatment date. * absence of physical or psychological conditions unacceptable to the investigator, especially those whom are contraindicated to receive treatments with ultherapy, belotero, radiesse and/or xeomin. * subjects who are identified with good photography, must have the ability to be contacted to provide authorization to disclose photographs for usage of previously taken photography, if photos are deemed worthy of publication. exclusion criteria: * subjects who have had any and all ultherapy treatment(s) before april 2013. * subjects who have not received radiesse®, xeomin®, and/or belotero balance® within 6 months of ultherapy treatment date. * psychiatric drugs and/or diseases that in the investigators opinion would impair the subject from understanding the photo consent, if photos are chosen for publication.
innovation in tuberculosis

Conditions: Tuberculosis

Summary: tuberculosis (tb) is one of the major infectious diseases worldwide, and the emergence and spread of drug resistant cases is a public health threat. however, the conventional methods used for diagnosis and drug-susceptibility testing are not enough for controlling the disease. in addition, all tb patients, independently of their age, gender, severity of the disease and type of responsible strain, follow the same treatment duration (up to 20 months in drug resistant cases), which often leads to high frequency of adverse events, suboptimal adherence to treatment, and poor outcome. therefore, a transition from programmatic to personalized management of tb is needed. innova4tb proposal will develop innovative technologies and approaches in order to improve the individual risk assessment for tb development, to rapidly diagnose active tb, to detect the drug susceptibility of the strain, to design tailor-made therapies, and to use biomarkers to guide and individualize the duration of antimicrobial therapy. this is of great importance for improving the quality of life of patients and ensuring treatment success, as well as for economic reasons for the healthcare system.


Eligibility criteria:
inclusion criteria: * immunosuppression will not be considered an exclusion criterion exclusion criteria: * patients who are not able to give their informed consent to participate in the study will be excluded
the effect of magnesium use in reversal of neuromuscular block with sugammadex

Conditions: Magnesium Sulfate; Pregnancy; Pre-Eclampsia; Neuromuscular Blockade

Summary: magnesium therapy used for seizure prophylaxis in patients with preeclampsia. magnesium has been shown to prolong the effect of nondepolarizing neuromuscular blocking agents (nmba) and neostigmine used to reverse the effect of nmba in general anesthesia . in this study, the investigators aimed to evaluate time from sugammadex injection to train-of-four ratio 0.9 who receieved magnesium therapy in reversing the effect of neuromuscular blocking agent during the recovery period and the relationship between magnesium level and duration of action of sugammadex

rapid-onset and short-acting agents should be preferred in induction, and full induction doses should be applied since they do not receive premedication and increased volume of distribution. rapid serial induction and intubation should be performed in pregnancies greater than 20 weeks due to the risk of aspiration. magnesium potentiates and prolongs the effect of nondepolarizing neuromuscular blocking agents. it is recommended that the tof value be between 0 and 2 for adequate muscle relaxation in cesarean section anesthesia. in anesthesia induction; thiopental 3-6mg/kg, rocuronium 1mg/kg, and fentanyl 1mcg/kg and dormicum 2mg will administered after the baby birth. sevoflurane 2-3% and 50% oxygen + 50% air are used for maintenance. if tof is 0, sugammadex 4mg/kg will be administered to reverse the effect of the muscle relaxant.a blood sample will be taken to measure simultaneous calcium and magnesium values. patients with a tof ≥0.9 (gold standard for extubation) or patients will be clinically evaluated and the decision to extubate will be made.

Eligibility criteria:
inclusion criteria: * pregnant women who are scheduled for cesarean section under general anesthesia (pregnant women who do not use magnesium) and who use magnesium for prophylaxis in preeclampsia. exclusion criteria: * eclampsia, * chronic hypertension, * connective tissue disorder, * muscle disease, neurological problems, * thyroid dysfunction, * kidney disease, heart disease, * patients with severe allergic reaction to the agents to be used, * sepsis, * hypovolemia, abruptio placenta, placenta previa, * conditions that will prolong the effect of muscle relaxants (drug use ), * pregnant women who did not want to be included in the study

Keywords: preeclampsi magnesium sulfate sugammadex
circulating biomarkers in the development of type 1 diabetes

Conditions: Diabetes

Summary: more than 100 million u.s. adults are now living with diabetes or prediabetes. investigators still do not fully understand how diabetes develops and how the disease worsens. insulin is a hormone that helps the body use sugar as a fuel and control blood-sugar levels. people with diabetes have problems making insulin. this is because their insulin-producing beta cells -in the pancreas-are damaged or destroyed. a biomarker is a biological molecule (such as dna, rna (the genetic material of cells) or protein) that is a sign of a normal or abnormal process, or of a condition or disease. a biomarker can be measured and found in blood and/or other body fluids (such as saliva and urine). understanding the biology of beta cells could help find diabetes-related biomarkers. the discoveries from this research could help with early diagnosis of diabetes and lead to the creation of therapies for treating diabetes.


Eligibility criteria:
inclusion criteria: * documented informed consent/ assent from the subject * one of the following: * type 1 diabetes patients (including pediatric patients) -or- * adult type 2 diabetes patients -or- * volunteers who are islet auto-antibody positive (i.e. insulin, gaa, ia-2, iaa and znt8 antibodies) with hba1c ≤ 5.6% (including pediatric patients)-or- * adult participants with clinical diagnosis of high blood sugar (i.e. hba1c of 5.7% to 6.4%)-or- * adult control subjects with hba1cc ≤ 5.6% * weight ≥ 30 kg * willingness to: provide blood sample(s) and if applicable: permit medical record/ clinical laboratory result review exclusion criteria: * control subjects must not have any chronic conditions or have undergone cellular, tissue or organ transplant * sickle cell disease or anemia (exception: anemia that is corrected with treatment and source documents confirm corrected blood parameters current within 6 months of blood draw) * active infection * active malignancy (i.e., currently undergoing treatment) * immunomodulatory therapy within 1 year of planned blood draw (may include immune checkpoint inhibitors, thalidomide, lenalidomide, pomalidomide, imiquimod, bacillus calmette-guérin, and cytokines/ growth factors (e.g. interferons, interleukins) * type 1 diabetes only: polyclonal regulatory t cell and/or dendritic cell therapy * bleeding disorder * women of childbearing potential: pregnant/ nursing (note: eligibility may be deferred per blood donation timelines for pregnancy/nursing) * diabetic patients only: any clinical condition that might be adversely affected by the removal of up to 100 ml of blood * an employee who is under the direct/ indirect supervision of the pi/ a co-investigator/ the study manager * a direct study team member
effect of cryotherapy on kinematic gait parameters in patients with chronic patellofemoral pain syndrome

Conditions: CHRONIC PATELLOFEMORAL PAIN SYNDROME

Summary: this study show the effect of cryotherapy on kinematic gait parameters in patients with chronic patellofemoral pain syndrome and review its reliability. participants were randomly allocated into two equal groups (a and b ) were done by a blinded independent researcher who opened enclosed envelopes containing computer generated randomization serially number index cards using statistical package for social science (spss),program (version 20 for windows ,spss, chicago illinois,usa) there were no dropouts among the participants throught the study after randomization.

sixty patients from both genders were participated in this study. they were selected from the outpatient clinic of faculty of physical therapy ,cairo university with a pfps. the patients of both genders with their ages were ranging from 18 to 40 years old and their bmi was from 20 to 25 kg/m2. thirty patients with pfps, their ages ranging from 18 to 40 years old ,their bmi was from 20 to 25 kg/m2 received treatment in form of traditional treatment (strengthening exercise, stretching, ultrasound and electrotherapy). the treatment performed three time a week for 4 weeks. thirty patients with pfps, their ages ranging from 18 to 40 years old ,their bmi was from 20 to 25 kg/m2 received treatment in form of traditional treatment (strengthening exercise, stretching, ultrasound and electrotherapy) with cryotherapy, the treatment performed three time a week for 4 weeks.

Eligibility criteria:
inclusion criteria: * the patients were diagnosed as patellofemoral pain by an orthopedist. * the participants were eligible to be included if they had bilateral pfps or unilateral pfps. * duration of knee pain is 4-5 weeks during 6 months prior to study. (collins et al., 2010). * their ages were ranging from 18 to 40 years (clin rheumatol et al., 2012). * their bmi was ranging from(20 to 25 kg/m2) (fischer et al., 2009) exclusion criteria: * • rheumatoid arthritis or other systemic rheumatic diseases. * dementia, psychosis. * active substance abuse disorder; acute or chronic disease, injury, deformity. * operation of the lower limb and knee. * severe hearing or visual impairment. * hospitalization for a cardiovascular condition, cerebral infarction or arrhythmia in the previous 3 months. * recent history of 3 or more falls. * current participation in another oa intervention study. * uncontrolled diabetes mellitus. * intra-articular knee injections in the previous 6 months. * contraindications to cryotherapy application those that feel a high level of discomfort or pain during the application.

Keywords: cryotherapy compression cryotherapy biodex gait trainer